Drug induced QT prolongation and torsades de pointes.
作者信息
Yap Yee Guan, Camm A John
机构信息
Department of Cardiological Sciences, St George's Hospital Medical School, London, UK.
出版信息
Heart. 2003 Nov;89(11):1363-72. doi: 10.1136/heart.89.11.1363.
Abstract
摘要
相似文献
1
Drug induced QT prolongation and torsades de pointes.
Heart. 2003 Nov;89(11):1363-72. doi: 10.1136/heart.89.11.1363.
2
Pharmacologic agents associated with QT interval prolongation.
J Fam Pract. 2005 Jun;Suppl:S8-S14.
3
Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.
BMJ. 2000 Apr 29;320(7243):1158-9. doi: 10.1136/bmj.320.7243.1158.
4
Drug-induced QT prolongation and sudden death.
Mo Med. 2010 Jan-Feb;107(1):53-8.
5
Drug-induced torsades de pointes in one patient with congenital long QT syndrome.
Int J Cardiol. 1996 Apr 19;54(1):85-8. doi: 10.1016/0167-5273(96)02582-x.
6
Drug-induced QT prolongation.
Isr Med Assoc J. 2000 Dec;2(12):924-8.
7
[Long QT-syndrome as a drug-induced side effect].
Duodecim. 1998;114(19):1891, 1893, 1895.
8
Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
Drug Saf. 2002;25(4):263-86. doi: 10.2165/00002018-200225040-00004.
9
Drug-induced q-T prolongation.
Med Clin North Am. 2005 Nov;89(6):1125-44, x. doi: 10.1016/j.mcna.2005.06.003.
10
Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.
Curr Cardiol Rep. 2004 Sep;6(5):379-84. doi: 10.1007/s11886-004-0041-8.
引用本文的文献
1
Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical analysis better?
BMC Med Inform Decis Mak. 2025 Aug 15;25(1):310. doi: 10.1186/s12911-025-03091-8.
2
A Comprehensive Review of a Mechanism-Based Ventricular Electrical Storm Management.
J Clin Med. 2025 Jul 29;14(15):5351. doi: 10.3390/jcm14155351.
3
Prioritizing repurposable drugs for Alzheimer's disease using network-based analysis with concurrent assessment of Long QT syndrome risk.
Biotechnol Rep (Amst). 2025 Jul 29;47:e00909. doi: 10.1016/j.btre.2025.e00909. eCollection 2025 Sep.
4
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.
J Antimicrob Chemother. 2025 Aug 1;80(8):2305-2313. doi: 10.1093/jac/dkaf210.
5
Broad Electrocardiogram Syndromes Spectrum: From Common Emergencies to Particular Electrical Heart Disorders-Part II.
Diagnostics (Basel). 2025 Jun 19;15(12):1568. doi: 10.3390/diagnostics15121568.
6
Practical Compendium of Antiarrhythmic Drugs: A Clinical Consensus Statement of the European Heart Rhythm Association of the ESC.
Europace. 2025 Mar 30. doi: 10.1093/europace/euaf076.
7
Cardiovascular Effects of Antiseizure Medications for Epilepsy.
CNS Drugs. 2025 Apr;39(4):383-401. doi: 10.1007/s40263-025-01163-x. Epub 2025 Feb 14.
8
Stereoselective block of the hERG potassium channel by the Class Ia antiarrhythmic drug disopyramide.
Cell Mol Life Sci. 2024 Nov 28;81(1):466. doi: 10.1007/s00018-024-05498-4.
9
Long-Term Antifungal Treatment in a Patient With Confirmed Allergic Bronchopulmonary Aspergillosis.
Cureus. 2024 Oct 22;16(10):e72142. doi: 10.7759/cureus.72142. eCollection 2024 Oct.
10
Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia.
Clin Transl Sci. 2024 Nov;17(11):e70065. doi: 10.1111/cts.70065.
本文引用的文献
1
The long-QT syndrome Genetic considerations.
Trends Cardiovasc Med. 1992 May-Jun;2(3):81-3. doi: 10.1016/1050-1738(92)90010-P.
2
A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia.
Jpn J Pharmacol. 2001 Nov;87(3):231-4. doi: 10.1254/jjp.87.231.
3
Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
Am J Gastroenterol. 2001 Jun;96(6):1698-703. doi: 10.1111/j.1572-0241.2001.03927.x.
4
QTc and psychotropic drugs.
Lancet. 2000 Jul 1;356(9223):75-6. doi: 10.1016/S0140-6736(05)73412-7.
5
The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.
J Pharmacol Exp Ther. 1998 Aug;286(2):788-93.
6
Risks of non-sedating antihistamines.
Lancet. 1997 May 3;349(9061):1322. doi: 10.1016/S0140-6736(97)26018-6.
7
Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.
J Antimicrob Chemother. 1996 May;37 Suppl A:161-7. doi: 10.1093/jac/37.suppl_a.161.
8
TCA cardiotoxicity: the latest.
J Am Acad Child Adolesc Psychiatry. 1996 Jun;35(6):701-2. doi: 10.1097/00004583-199606000-00006.
9
Cisapride and fatal arrhythmia.
N Engl J Med. 1996 Jul 25;335(4):290-1. doi: 10.1056/NEJM199607253350416.
10
Mechanism of the cardiotoxic actions of terfenadine.
JAMA. 1993;269(12):1532-6.
Zotero 插件